|
MYCBP expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 6.9931999968631E-08 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
8.60869999952385E-07 |
| Normal-vs-Stage2 |
6.884400E-02 |
| Normal-vs-Stage3 |
1.90410000000529E-06 |
| Normal-vs-Stage4 |
2.57389998203905E-10 |
| Stage1-vs-Stage2 |
2.610800E-01 |
| Stage1-vs-Stage3 |
3.069200E-01 |
| Stage1-vs-Stage4 |
3.223100E-03 |
| Stage2-vs-Stage3 |
9.576000E-02 |
| Stage2-vs-Stage4 |
2.844600E-03 |
| Stage3-vs-Stage4 |
6.082400E-02 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
7.59099999525503E-08 |
| Normal-vs-AfricanAmerican |
1.815670E-02 |
| Normal-vs-Asian |
5.19600000026266E-07 |
| Caucasian-vs-AfricanAmerican |
9.460400E-01 |
| Caucasian-vs-Asian |
4.435400E-01 |
| AfricanAmerican-vs-Asian |
6.798800E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
3.78879999995974E-06 |
| Normal-vs-Female |
1.44259999945717E-07 |
| Male-vs-Female |
8.936200E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
2.01620000028768E-07 |
| Normal-vs-Age(41-60Yrs) |
1.8810099999933E-05 |
| Normal-vs-Age(61-80Yrs) |
4.83659999994668E-06 |
| Normal-vs-Age(81-100Yrs) |
9.908400E-02 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
5.145400E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
7.600000E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
4.788200E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
4.314200E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
7.098600E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
4.956200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
1.16010000050792E-07 |
| Classical-VS-Follicular |
5.172400E-01 |
| Classical-VS-Other |
1.636980E-01 |
| Classical-VS-Normal |
3.99429999997647E-06 |
| Tall-VS-Follicular |
1.61744999999103E-05 |
| Tall-VS-Other |
8.198400E-01 |
| Tall-VS-Normal |
1.77124981348697E-12 |
| Follicular-VS-Other |
1.740820E-01 |
| Follicular-VS-Normal |
3.556900E-03 |
| Other-VS-Normal |
3.494200E-02 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
5.72079999999753E-05 |
| Normal-vs-N1 |
3.31889959959142E-10 |
| N0-vs-N1 |
6.150400E-04 |
|
|
